Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. by Bihan, A. Le et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/165932
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
RESEARCH ARTICLE
Characterization of Novel Antimalarial
Compound ACT-451840: Preclinical
Assessment of Activity and Dose–Efficacy
Modeling
Ame´lie Le Bihan1, Ruben de Kanter1, Iñigo Angulo-Barturen2, Christoph Binkert1,
Christoph Boss1, Reto Brun3,4, Ralf Brunner1,3,4, Stephan Buchmann1, Jeremy Burrows5,
Koen J. Dechering6, Michael Delves7, Sonja Ewerling1, Santiago Ferrer2,
Christoph Fischli3,4, Francisco Javier Gamo–Benito2, Nina F. Gna¨dig8, Bibia Heidmann1,
Marı´a Bele´n Jime´nez-Dı´az2, Didier Leroy5, Maria Santos Martı´nez2, Solange Meyer1, Joerg
J. Moehrle5, Caroline L. Ng8, Rintis Noviyanti9, Andrea Ruecker7, Laura Marı´a Sanz2,
Robert W. Sauerwein6, Christian Scheurer3,4, Sarah Schleiferboeck3,4, Robert Sinden7,
Christopher Snyder1, Judith Straimer8, Grennady Wirjanata10, Jutta Marfurt10, Ric
N. Price10,11, Thomas Weller1, Walter Fischli1, David A. Fidock8,12, Martine Clozel1,
Sergio Wittlin3,4*
1 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 2 GlaxoSmithKline, TresCantos Medicines
Development Campus, Diseases of the Developing World, Tres Cantos, Madrid, Spain, 3 Swiss Tropical
and Public Health Institute, Basel, Switzerland, 4 University of Basel, Basel, Switzerland, 5 Medicines for
Malaria Venture, Geneva, Switzerland, 6 TropIQ Health Sciences B.V., Nijmegen, The Netherlands,
7 Department of Life Sciences, Imperial College London, SW7 2AZ, London, United Kingdom,
8 Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York,
United States of America, 9 Eijkman Institute for Molecular Biology, Jakarta, Indonesia, 10 Global and
Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin,
Australia, 11 Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine,
University of Oxford, Oxford, United Kingdom, 12 Division of Infectious Diseases, Department of Medicine,
Columbia University Medical Center, New York, New York, United States of America
* sergio.wittlin@unibas.ch
Abstract
Background
Artemisinin resistance observed in Southeast Asia threatens the continued use of artemisi-
nin-based combination therapy in endemic countries. Additionally, the diversity of chemical
mode of action in the global portfolio of marketed antimalarials is extremely limited.
Addressing the urgent need for the development of new antimalarials, a chemical class of
potent antimalarial compounds with a novel mode of action was recently identified. Herein,
the preclinical characterization of one of these compounds, ACT-451840, conducted in
partnership with academic and industrial groups is presented.
Method and Findings
The properties of ACT-451840 are described, including its spectrum of activities against
multiple life cycle stages of the human malaria parasite Plasmodium falciparum (asexual
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and sexual) and Plasmodium vivax (asexual) as well as oral in vivo efficacies in two murine
malaria models that permit infection with the human and the rodent parasites P. falciparum
and Plasmodium berghei, respectively. In vitro, ACT-451840 showed a 50% inhibition con-
centration of 0.4 nM (standard deviation [SD]: ± 0.0 nM) against the drug-sensitive P. falcip-
arum NF54 strain. The 90% effective doses in the in vivo efficacy models were 3.7 mg/kg
against P. falciparum (95% confidence interval: 3.3–4.9 mg/kg) and 13 mg/kg against P.
berghei (95% confidence interval: 11–16 mg/kg). ACT-451840 potently prevented male
gamete formation from the gametocyte stage with a 50% inhibition concentration of 5.89
nM (SD: ± 1.80 nM) and dose-dependently blocked oocyst development in the mosquito
with a 50% inhibitory concentration of 30 nM (range: 23–39). The compound’s preclinical
safety profile is presented and is in line with the published results of the first-in-man study in
healthy male participants, in whom ACT-451840 was well tolerated. Pharmacokinetic/phar-
macodynamic (PK/PD) modeling was applied using efficacy in the murine models (defined
either as antimalarial activity or as survival) in relation to area under the concentration ver-
sus time curve (AUC), maximum observed plasma concentration (Cmax), and time above a
threshold concentration. The determination of the dose–efficacy relationship of ACT-
451840 under curative conditions in rodent malaria models allowed prediction of the human
efficacious exposure.
Conclusion
The dual activity of ACT-451840 against asexual and sexual stages of P. falciparum and
the activity on P. vivax have the potential to meet the specific profile of a target compound
that could replace the fast-acting artemisinin component and harbor additional gametocyto-
cidal activity and, thereby, transmission-blocking properties. The fast parasite reduction
ratio (PRR) and gametocytocidal effect of ACT-451840 were recently also confirmed in a
clinical proof-of-concept (POC) study.
Author Summary
Why Was This Study Done?
• The limited diversity of chemical mode of action in the global portfolio of marketed anti-
malarials along with recently observed artemisinin resistance that threatens the current
first-line treatment highlights the urgent need for development of new antimalarials.
• In accordance with target product profiles defined by the Medicines for Malaria Venture
([MMV]; www.mmv.org), a newmodel of not-for-profit public–private partnership pro-
viding guidance to the development of new drugs, ACT-451840, a new chemical class of
potent compounds with a novel mode of action, was selected for early development.
• This manuscript integrates a number of studies performed to characterize preclinically
ACT-451840 and illustrates the new antimalarial drug development paradigm.
Preclinical Assessment of Novel Antimalarial Compound ACT-451840
PLOS Medicine | DOI:10.1371/journal.pmed.1002138 October 4, 2016 2 / 24
manuscript. DAF also gratefully acknowledges NIH
funding (R01 AI109023), and RNP received
funding from The Wellcome Trust (091625).
Competing Interests: I have read the journal’s
policy and the following authors of this manuscript
have the following competing interests: KJD holds
stocks in TropIQ Health Sciences. IAB, SF, FJGB,
MBJD, MSM, LMS were employed by and owned
shares of GlaxoSmithKline while conducting the
studies presented. ALB, RDK, CBi, CBo, RaB, SB,
SE, BH, SM, CSn,TW, WF, MC were employed by
and owned shares of Actelion Pharmaceuticals Ltd
while conducting the studies presented.
Abbreviations: AUC, Area under the concentration
versus time curve; B.i.d., bis in die (bi-daily); Cmax,
Maximum observed plasma concentration; CQ,
Chloroquine; CYC, Cycloguanil; DMSO, Dimethyl
sulfoxide; ED50, 50% effective dose; ED90, 90%
effective dose; E0, Minimal effect; Emax, Maximal
effect; GSK, GlaxoSmithKline; IC50, 50% inhibitory
concentration; IC90, 90% inhibitory concentration;
IC99, 99% inhibitory concentration; LC-MS/MS,
Liquid chromatography coupled to tandem mass
spectrometry; MFQ, Mefloquine; MMV, Medicines
for Malaria Venture; MR4, Malaria Research and
Reference Reagent Resource Center; NMRI, Naval
Medical Research Institute; PD,
Pharmacodynamics; PfMDR1, P. falciparum
multidrug resistance protein-1; PK,
Pharmacokinetics; POC, Proof-of-concept; PRR,
Parasite reduction ratio; PYR, Pyrimethamine; q.d.,
Quaque die (once a day); RPMI, Roswell Park
Memorial Institute medium; RSA0-3h, Ring-stage
survival assay; SD, Standard deviation; SE,
Standard error; SERCaP, Single Exposure Radical
Cure and Prophylaxis; SUL, Sulfadoxine; Swiss
TPH, Swiss Tropical and Public Health Institute;
TCP, Target compound profile; Tmax, Time to
reach the maximum observed plasma
concentration; WHO, World Health Organization.
What Did the Researchers Do and Find?
• This study used in vitro models to investigate compound activity on sexual and asexual
blood stages and a mouse model to study the human parasite P. falciparum in vivo.
• While being fully active against artemisinin-resistant strains, ACT-451840 shares many
of the favorable properties of artemisinins like its fast onset of action, activity against all
asexual blood stage forms, and a PRR of>4 log per parasite cycle.
• Pharmacodynamic properties of ACT-451840 were interpreted in two mouse models of
malaria with respect to the pharmacokinetic properties, with the objective to establish
the portable PK/PD parameters to estimate efficacious exposure.
What Do These Findings Mean?
• Modeling the dose–efficacyrelationship of ACT-451840 supported prediction of the
human efficacious exposure and therefore laid the groundwork for the new clinical
development phases.
• Confirmed in an experimental human malaria infectionmodel, the properties of ACT-
451840, including its fast action observed in in vitro and in vivo models and its transmis-
sion-blocking activity, suggest this compoundmay be able to replace the artemisinin
component in artemisinin-basedcombination therapy.
Introduction
Malaria caused 438,000 deaths worldwide in 2015, of which 70% were in children under the
age of 5 y [1]. Between 2000 and 2015, strategies for malaria control and eradication reduced
the incidence of malaria by 48% in theWHO African Region. The upscaled interventions con-
sisted of increased accessibility to long-lasting insecticidal bed nets, protection of the popula-
tion at risk by indoor residual spraying, and increased access to rapid diagnostic tests and
artemisinin-basedcombination therapies. However, with the detection of parasite resistance to
artemisinin, the core compound of artemisinin-based combination therapies, in five countries
of Southeast Asia, the availability of efficacious combination therapies is under threat [1].
Additionally, not a single new chemical class of antimalarials has been registered since 1996
[2], and the current global portfolio of antimalarial compounds in late clinical development
relies largely on novel combinations of existing drugs, not novel compounds [3]. These ele-
ments highlight the critical and urgent need for new drugs to treat malaria.
In this search, ACT-213615, a compound from Actelion Pharmaceuticals Ltd. (ACT) with a
mode of action distinct from that of all registered antimalarials, was recently described [4]. The
compound was discovered in a phenotypic screen and showed potent and fast-acting activity
in in vitro assays against all asexual erythrocyticstages of P. falciparum (i.e., rings, trophozoites,
and schizonts). Further investigations regarding the mode of action established an interaction
of this compound class with P. falciparum multidrug resistance protein-1 (PfMDR1) [5,6].
The present work illustrates a novel antimalarial drug development process, in that the stud-
ies were performed in partnership with research groups around the globe from industry and
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academia.MMV (Geneva, Switzerland), a newmodel of not-for-profit public–private partner-
ship, was instrumental in the establishment of those collaborations and has transformed the
field of malaria therapy by providing guidance to the development of new drugs. The strategy
of MMV is the prioritization of new treatments that provide a single exposure radical cure and
prophylaxis (SERCaP). Prevention of transmission, prevention of relapse following infection
by P. vivax and Plasmodium ovale, and significant post-treatment prophylaxis are the key
properties sought for future medicines, as described in MMV's new target compound profiles
(TCP) [7]. Achievement of the SERCaP objectivesmight require the combination of several
compounds (two to three), each with specific profiles and properties. Ideally, a newmalaria
treatment requires at least one molecule capable of replacing the fast-acting artemisinin com-
ponent described as target compound profile 1 (TCP1). Suitability as a TCP1 candidate can be
assessed in experiments (A) determining potency in both P. falciparum and P. vivax strains,
(B) including strains already resistant to other antimalarials including artemisinins, (C) mea-
suring log kill in vitro in comparison to existing antimalarials, and (D) establishing efficacy in
an appropriate in vivo animal model. The TCP2-typemolecules would be used as long dura-
tion combination partners that complete the clearance of the blood stage parasites not elimi-
nated by TCP1 molecules. Understanding the PK profile of a compound will determine its
suitability as a TCP2 candidate. Molecules with a potential for blocking transmission should
target mature gametocytes (TCP3b) and also antagonize other nondividing parasites such as
hypnozoites (TCP3a). Finally, molecules blocking the infection of the host liver by sporozoites,
or killing liver schizonts, will cover the need for TCP4 drugs [8].
Leveraging these TCPs, the continuous drug discovery effort in the new class of potent anti-
malarials around ACT-213615 led to the selection of ACT-451840. In the present study, the
characterization of ACT-451840 is used to illustrate the new drug development paradigm in
which new technical expertise and model-basedmethodologies are being used to improve the
subsequent clinical development phases and reduce attrition rates. Firstly, the experiments to
evaluate the biological potential of ACT-451840 in P. falciparum in vitro assays against all asex-
ual erythrocytic stages and against a panel of clinical isolates including P. vivax are shown.
Additionally, key PD properties of the compound are described, including its precise rapidity
of action and parasite log kill, efficacy in two pharmacologicalmurine models with both
human and mouse malaria parasites, and in vitro inhibition of gamete formation from the
male gametocyte stage, resulting in transmission blocking in mosquitoes. Finally, the modeling
of efficacy in murine models defined either as antimalarial activity, or as survival, in relation to
AUC, Cmax, and time over a threshold concentration, was used to determine the dose–efficacy
relationship of ACT-451840. The subsequent prediction of the human efficacious exposure
was used to guide the dose selection for the initiation of the POC study. The goal of the here
describedpreclinical assessment of activity and dose–efficacymodeling of ACT-451840 was to
lay the groundwork for the next phases of clinical development.
Methods
Ethics Statement
Animal experiments performed at Actelion Pharmaceuticals and at the Swiss Tropical and
Public Health Institute (Swiss TPH), or performed at GlaxoSmithKline (GSK) were approved,
respectively, by the Swiss Cantonal Authorities and by the Diseases of the DevelopingWorld
Ethical Committee on Animal Research. The animal studies carried out at GSK were in accor-
dance with European Directive 2010/63/EU and the GSK Policy on the Care, Welfare and
Treatment of Animals and were accredited by the Association for Assessment and Accredita-
tion of Animal Laboratory Care for the ones performed at Diseases of the DevelopingWorld
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Laboratory Animal Science facilities. The results from the animal experiments are reported as
per ARRIVE guidelines (S1 Checklist). The human biological samples were sourced ethically,
and their research use was in accord with the terms of the informed consents. Ethical approval
for the field studies were obtained from the Human Research Ethics Committee of the North-
ern Territory Department of Health & Families and Menzies School of Health Research, Dar-
win, Australia (HREC 2010–1396), and the Eijkman Institute Research Ethics Commission,
Jakarta, Indonesia (EIREC 47).
Synthesis of ACT-451840
The synthesis of ACT-451840 developed at Actelion Pharmaceuticals (Allschwil, Switzerland)
is shown in the supportingmaterial (S1 Fig). ACT-451840 is patented (WO 2011/083413).
In Vitro Antimalarial Activity against P. falciparum
The in vitro antimalarial activity of ACT-451840 was measured at the Swiss TPH (Basel, Swit-
zerland) using the [3H]-hypoxanthine incorporation assay [9]. Results were expressed as the
concentration resulting in 50% inhibition (IC50). In vitro time-, stage-, and concentration-
dependent effects were assessed using pyrimethamine as a stage-specific and slow-acting con-
trol, as described elsewhere [10].
In Vitro Antimalarial Activity against P. falciparum Artemisinin-Resistant
Strains
Ring-stage survival assays (RSA0-3h) were carried out at Columbia University Medical Center
(New York, United States) as previously described [11,12]. Parasite cultures were synchronized
using 5% sorbitol (Sigma-Aldrich), and schizonts were incubated in RPMI-1640 containing 15
units/ml sodium heparin for 15 min at 37°C to disrupt agglutinated erythrocytes.These schiz-
onts were concentrated over a gradient of 75% Percoll (Sigma-Aldrich), washed once in RPMI-
1640, and incubated for 3 h with fresh erythrocytes to allow time for merozoite invasion. Cul-
tures were then subjected again to sorbitol treatment to eliminate remaining schizonts. The
0–3 h postinvasion rings were adjusted to 1% parasitemia and 2% hematocrit in 1 mL volumes
(in 48-well plates) and exposed to a range of ACT-451840 drug concentration (700–35 nM) or
0.1% DMSO for 6 h. Duplicate wells were established for each parasite line ± drug concentra-
tion. One-mL cultures were then transferred to 15-mL conical tubes, centrifuged at 800xg for 5
min to pellet the cells, and the supernatants carefully removed. As a washing step to remove
drug, 10 mL culture mediumwere added to each tube, and the cells were resuspended, centri-
fuged, and the mediumwas aspirated. Fresh mediumwithout drug was then added to cultures,
which were returned to standard culture conditions for 66 h. A media change was performed,
and parasite viability was assessed by flow cytometry at 96 h. Stained parasites were detected
using a BD Accuri 6 Flow Cytometer and analyzed using FlowJo Software. IC50 values were
determined by nonlinear regression using GraphPad Prism 6.0. For statistical analyses, Stu-
dent’s t tests were performed, and significancewas set at p< 0.05.
Ex Vivo Drug Susceptibility against Multidrug-Resistant P. falciparum
and P. vivax Clinical Isolates
Ex vivo drug susceptibility testing in P. falciparum and P. vivax (often a mix of rings, trophozo-
ites, and schizonts) was assessed in clinical isolates at the Timika Research Facility (Papua,
Indonesia), an area with confirmedhigh levels of multidrug resistance to chloroquine, sulfa-
doxine-pyrimethamine, and amodiaquine in both species [13–15]. Thick blood filmsmade
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from each well were stained with 5% Giemsa solution for 30 min and examinedmicroscopi-
cally. The number of schizonts per 200 asexual-stage parasites was determined for each drug
concentration and normalized to the control well. The dose–response data were analyzed using
nonlinear regression analysis (WinNonLin 4.1, Pharsight Corporation), and the concentrations
resulting in 50% inhibition (IC50) were derived using an inhibitory sigmoid Emax model. Ex
vivo IC50 data were only used from predicted curves for which the E0 and Emax were within
15% of 1 and 100, respectively.
In Vitro Parasite Reduction Ratio
In vitro PRR testing was conducted at GSK (Tres Cantos, Madrid, Spain) as previously
described [16]. The assay used the limiting dilution technique to quantify the number of para-
sites that remained viable after drug treatment. P. falciparum strain 3D7 (MR4) was treated
with drug concentration corresponding to 10 x IC50. Conditions of parasites exposed to treat-
ment were identical to those used at GSK in the IC50 determination (2% hematocrit, 0.5% para-
sitemia). Parasites were treated for 120 h. Drug in culture mediumwas renewed daily over the
entire treatment period. Parasite samples were collected from the treated culture every 24 h
(24, 48, 72, 96, and 120 h time points); drug was washed out of the sample, and parasites were
cultured drug-free in 96-well plates by adding fresh erythrocytes and culture medium. To
quantify the number of viable parasites after treatment, 3-fold serial dilutions were used with
the above mentioned samples after removing the drug. Four independent serial dilutions were
performedwith each sample to correct experimental variations. The number of viable parasites
was determined after 21 and 28 d by counting the number of wells with growth using [3H]-
hypoxanthine incorporation. The number of viable parasites was back-calculated by using the
formula Xn-1 where n is the number of wells able to render growth and X the dilution factor
(when n = 0, number of viable parasites is estimated as zero) [16]. The PRR, defined as the log-
arithm to base 10 of the number of parasites the drug can kill in one parasite life cycle and indi-
cating the killing rate of the compound investigated, was calculated as the decrease in viable
parasites over 48 h. A lag phase was considered to occur for as long as drug treatment did not
produce the maximal rate of killing, and this period of time was excluded for PRR calculation.
The parasite clearance time to kill 99.9% of the initial population was determined using a
regression calculated on the log-linear phase of the parasite reduction, taking into account the
lag phase.
In Vitro Antimalarial Activity against P. berghei
In vitro (ex vivo) activity against the mouse malaria parasite P. berghei was measured at the
Swiss TPH as described elsewhere [17], with the followingmodifications: heparinised blood of
P. berghei infected and uninfected control female NMRImice (final hematocrit of 2.5%) was
used and exposed to compounds for 16 h followed by 8 h of [3H]-hypoxanthine incorporation.
In Vivo Antimalarial Efficacy Studies
In vivo efficacy against P. berghei was conducted at the Swiss TPH as previously described [18],
with the modification that female NMRI mice fromHarlan (Horst, The Netherlands) (n = 3)
were infected with a GFP-transfected P. berghei ANKA strain (kindly donated by A. P. Waters
and C. J. Janse, LeidenUniversity Medical Center, The Netherlands) and parasitemia was
determined using standard flow cytometry techniques. ACT-451840 was dissolved or sus-
pended in corn oil before dosing and administered 24 h after infection (single-dose regimen)
or 24, 48, and 72 h after infection (triple-dose regimen).With the single-dose regimen, blood
was collected on Day 3 (72 h after infection). Samples for the triple-dose regimens were
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collected on Day 4 (96 h after infection). Antimalarial activity was calculated as the difference
between the mean percent parasitemia for the control and treated groups expressed as a per-
cent relative to the control group, consisting of five mice. Control mice were euthanized on
Day 4 in order to prevent death typically occurringon Day 6. For the consistency in PK/PD
modeling, Day 5 instead of Day 6 was considered the day of death, because treated animals
were always euthanized one day before their natural death for animal welfare reasons. Animals
were considered cured if there were no detectable parasites on Day 30 post-infection. To con-
firm the reliability of this assumption, blood from the survivingmice in curative experiments
was inoculated into uninfectedmice, and no parasitemia developed in these mice even after 30
d [19]. The antimalarial efficacy is defined either as antimalarial activity or as survival: the two
readouts of the P. bergheimurine model.
In vivo efficacy against P. falciparum was conducted at GSK according to the standard assay
previously described [20,21]. Female NODscidIL2Rγnullmice were engrafted with human
erythrocytes and infected with the isolate P. falciparum PfNF540230/N3, a strain developed at
GSK for growth in engraftedmice. At Day 3 after infection, chloroquine (at 2 or 5 mg/kg) or
ACT-451840 (3, 10, 30, or 100 mg/kg; n = 3 mice per dose, formulated in corn oil) were dosed
via oral gavage once a day for four consecutive days (quadruple-dose regimen). Blood samples
were collected on Days 3, 4, 5, 6, and 7 (n = 3 per time point) for parasitemia measurement by
flow cytometry. Similarly, blood samples were collected at 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 h after
a single administration of 4.7 mg/kg of ACT-451840 to a parallel group of three P. falciparum-
infectedmice for PK parameters determination. Results are expressed exclusively as antimalar-
ial activity in the P. falciparum murine model.
P. falciparum Dual Gamete Formation Assay (Pf DGFA)
Mature P. falciparum NF54 gametocytes were cultured at Imperial College London (London,
United Kingdom), as previously described [22]. The cultures, which displayed between 0.2 and
0.4% exflagellation centers as a percentage of the total blood cell population, were then taken
and divided into 96-well plates containing ACT-451840 in dose response (range 0.84 nM–
20 μM). Final DMSO concentration in the assay did not exceed 0.25%. Plates were incubated
for 24 h in the presence of ACT-451840 before male and female gametocyte viability was
assessed by stimulating gamete formation by temperature decrease from 37°C to ~22°C and
the addition of the gametocyte activating factor xanthurenic acid (5 μM). Male gamete forma-
tion was quantified by computer-aided automated identification and counting of exflagellation
centers. Female gamete formation was visualized by live immunofluorescencewith a Cy3-con-
jugated antibody specific for Pfs25—a female gamete expressed surface protein. Gamete forma-
tion was expressed as a percent inhibition, taking into consideration DMSO-negative control
wells and 10 μMmethylene blue-positive control wells, methylene blue being a potent inhibitor
of the functional viability of male and female stage V gametocytes [22]. IC50 values were calcu-
lated using GraphPad Prism version 6 using the logarithmic versus normalized response (vari-
able slope) function (Graphpad Software, San Diego, US).
Oocyst Density Evaluation by Standard Membrane Feeding Assay
ACT-451840 was tested in the standard membrane feeding assay at TropIQ (Nijmegen, The
Netherlands) in two modes, as previously described [23]. In the direct mode, the compound
was directly added to a bloodmeal containing mature stage V gametocytes that was fed to
Anopheles stephensi mosquitoes. In the indirect mode, mature stage V gametocytes were pre-
exposed for 24 h to a serial dilution of compound (10−5 to 10−9 M final concentration) prior to
mosquito feeding. Gametocytes were adapted to a hematocrit of 50% in full serum and fed to
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A. stephensi mosquitoes. Seven days after the bloodmeal, the number of oocysts in the midgut
was determined by microscopy for both modes. ACT-451840 was tested in duplicate in a
9-point dose response series (1010–106 M in 0.5 log dilutions). Vehicle control (0.1% DMSO)
and positive control (10 μM dihydroartemisinin) were included. Twenty mosquitoes were dis-
sected per sample, and oocyst load was analyzed per mosquito. All assays passed the quality
control criterion of>50% infectedmosquitoes in the control cages.
Pharmacokinetic Studies
Female NMRImice were purchased from Harlan (Horst, The Netherlands) by Actelion Phar-
maceuticals. ACT-451840 was formulated as a solution in corn oil and dosed via oral gavage at
10, 100, and 300 mg/kg. Serial blood samples were collected at 0.5, 2, 4, and 8 h after dosing
from two mice and after 1, 3, 6, and 24 h from two other mice, creating composite PK profiles
from, in total, four mice per dose. Blood samples were analyzed using liquid chromatography
coupled to tandemmass spectrometry (LC-MS/MS) after protein precipitation. PK parameters
were estimated using non-compartmental analysis from the composite profiles.
Pharmacokinetic/Pharmacodynamic Modeling
A single compartment PK model with saturable absorption was obtained using naïve pooling
to fit simultaneously the observedblood concentration time data from the PK studies done at a
dose of 10, 100, and 300 mg/kg, as described above. Using this model, blood concentration
time profiles were predicted for all dosing regimens used in the mouse antimalarial efficacy
studies. Cmax, AUC, and time above a threshold concentration were subsequently calculated
using non-compartmental analysis. PD modeling was done using an Emax model using Cmax,
AUC, or time above a threshold concentration versus survival or antimalarial activity. All
modeling and PK analyses were done using PhoenixWinonlin 6.3 (Cetara, Princeton, US).
Results
Characterization of ACT-451840 In Vitro and In Vivo against Asexual
Blood Stage: Biological Activity against Relevant Parasites
Antimalarial asexual blood-stage activity of ACT-451840 was evaluated against a panel of P.
falciparum culture adapted isolates by a [3H] hypoxanthine incorporation assay (Table 1).
ACT-451840 showed a low nanomolar activity against the drug-sensitiveP. falciparum NF54
strain (mean IC50 = 0.4 ± 0.0 nM; IC90 = 0.6 ± 0.0 nM; IC99 = 1.2 ± 0.0 nM, n 3; ± SD) and
Table 1. In vitro activity against a panel of resistant and sensitive strains of P. falciparum.
Isolate (origin) Resistance 50% inhibitory concentration (IC50) (nM)
ACT-451840 AS CQ PYR
NF54(West Africa) No resistance 0.4 ± 0.0 3.7 ± 0.5 11 ± 2.1 18 ± 0.8
K1(Thailand) CQ, SUL, PYR, CYC 0.3 ± 0.0 2.7 ± 0.4 303 ± 37 10,138 ± 705
W2(Vietnam) CQ, SUL, PYR, CYC 0.2 ± 0.1 2.4 ± 0.7 326 ± 38 13,923 ± 3525
7G8(Brazil) CQ, PYR, CYC 0.3 ± 0.1 1.8 ± 0.2 137 ± 21 10,484 ± 2574
TM90C2A(Thailand) CQ, PYR, MFQ, CYC 1.0 ± 0.3 4.6 ± 1.7 174 ± 19 19,248 ± 3876
V1/S(Vietnam) CQ, SUL, PYR, CYC 0.3 ± 0.0 3.2 ± 0.5 458 ± 66 21,936 ± 1072
D6(Sierra Leone) MFQ 0.5 ± 0.1 7.1 ± 1.9 16 ± 1.2 5.4 ± 1.3
Abbreviations: chloroquine (CQ), pyrimethamine (PYR), cycloguanil (CYC), sulfadoxine (SUL), mefloquine (MFQ). Data are the means ± SD of n = 3
independent [3H] hypoxanthine incorporation experiments (each run in duplicate).
doi:10.1371/journal.pmed.1002138.t001
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was almost equally active against a number of drug-resistant isolates. The IC50 values of the
control compounds, e.g., artesunate, chloroquine, and pyrimethamine, against the NF54 strain
were 3.7 ± 0.5 nM, 11 ± 2.1 nM, and 18 ± 0.8 nM, respectively.
Antimalarial asexual blood-stage activity of ACT-451840 was also evaluated against a Cam-
bodian clinical isolate (Cam3.II, which has a K13 R539T mutation) that was gene-edited to the
wild-typeK13 gene (Cam3.IIrev) and against Cam3.IIC580Y, a gene-edited line that is artemisi-
nin resistant and encodes the C580Ymutation in the K13 gene [11,12]. The mutation C580Y,
conferring resistance to artemisinin, was found to not alter parasite susceptibility to ACT-
451840, mefloquine, or artesunate in conventional 72-h dose–response assays that determine
IC50 growth inhibition values on both the Cam3.II and V1/S backgrounds (S1 Text). Addition-
ally, both Cam3.II lines were subjected to the recently developed ring-stage survival assay
(RSA0-3h), in which parasites were exposed for a 6-h pulse to a range of drug concentration
(35–700 nM), and parasite survival was assessed 66 h later [11,12]. No difference in survival
rates was observedbetween the parasite harboring a wild-typeK13 allele or the C580Ymuta-
tion (Fig 1), confirming that ACT-451840 is fully efficacious against artemisinin-resistant para-
sites. In contrast, the C580Y strain showed the expected grade of resistance versus the exposure
to 700 nM dihydroartemisinin [11,12].
Fig 1. K13 propeller mutation C580Y confers no cross-resistance to ACT-451840 in ring-stage survival
assays (RSA0-3h). Graph shows mean ± standard error (SE) ring-stage survival values in the RSA0-3h. At least two
biological replicates were performed per line, each consisting of two technical replicates Cam3.IIC580Y (dotted line)
and Cam3.IIrev (solid line). Abbreviation: ring-stage survival assay (RSA0-3h).
doi:10.1371/journal.pmed.1002138.g001
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In ex vivo assays against a range of clinical isolates collected from patients with malaria from
Papua, Indonesia, a region where multidrug-resistantmalaria is endemic, ACT-451840 was as
potent as artesunate against both P. falciparum (median IC50 = 2.5 [Range 0.9–9.0] nM, n = 27)
and P. vivax (median IC50 = 3.0 [Range 0.5–16.8] nM, n = 34) (Fig 2). The IC50 value of ACT-
451840 against the murinemalaria parasite P. bergheiwas 13.5 nM in in vitro ex vivo assays.
In an in vitro PRR assay [16], ACT-451840 showed a fast parasite killing profile against P.
falciparum similar to that of chloroquine (log PRR of 4.4 and 4.5, respectively) without lag
phase in the killing curve in contrast to atovaquone (48 h). The parasite clearance time to kill
99.9% of the initial population was 28 h for ACT-451840, similar to that of artemisinin and
chloroquine (less than 24 h and 32 h, respectively) (Fig 3). In vitro stage specificity assays [24]
with synchronous cultures of P. falciparum NF54 were consistent with this rapid killing rate.
ACT-451840 rapidly reduced parasite growth and affected all asexual erythrocyticstages
equally in a time- and concentration-dependent manner, similar to artemether (Fig 4) [24].
In vivo activity of ACT-451840 was assessed in the P. falciparummousemodel established at
GSK (DDW, Tres Cantos, Spain). After an oral quadruple-dose regimen,ACT-451840 had a
rapid onset of action and an effective dose, resulting in 90% antimalarial activity (ED90) of 3.7 mg/
kg (3.3–4.9mg/kg), which was comparable to the one of chloroquine (ED90 of 4.9 mg/kg) (Fig 5).
In a P. bergheimouse model, the ED90 after an oral triple-dose regimen of ACT-451840 was
13 mg/kg (11–16 mg/kg) (calculated from the data in S2 Text). This ED90 value was about
4-fold higher than the one observed in the P. falciparum mouse model (ED90 3.7 mg/kg). The
Fig 2. Ex vivo drug susceptibility. Median 50% inhibitory concentrations (IC50s) of standard antimalarials and ACT-451840 in P. falciparum
(closed symbols; n = 27) and P. vivax (open symbols; n = 34) clinical isolates.
doi:10.1371/journal.pmed.1002138.g002
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difference in in vivo activities correlates with the difference in in vitro ex vivo activities of
ACT-451840 against P. berghei (IC50 13.5 nM, see above) and P. falciparum ex vivo (IC50 2.5
nM, clinical isolates; Fig 2). Despite the lower activity of ACT-451840 against P. berghei, 20%
and 100% of the infectedmice were cured after 100 and 300 mg/kg triple-dose regimen, respec-
tively (Fig 6 and S2 Text). In the same in vivo model, artesunate, the semisynthetic derivative
of artemisinin, cured 50% of the mice at 100 mg/kg after a quadruple-dose regimen.
In summary, ACT-451840 had an IC50 below 10 nM in vitro against a panel of sensitive and
resistant strains of P. falciparum and was fully active against recently identified artemisinin-resis-
tant strains. Furthermore, the compound showed ex vivo activity against P. falciparum and P. vivax
as well as a single digit mg/kg ED90 in a P. falciparummurinemodel. In addition, the compound
inhibited growth of all asexual blood stages of P. falciparum in vitro, and its in vitro PRR was simi-
lar to that of chloroquine. These key properties fullymeet the criteria described in TCP1 [8].
Characterization of ACT-451840 In Vitro against Sexual Blood Stage:
Potential for Blocking Transmission
Using two bioassays, the effects of ACT-451840 on the functional viability of both male and
female mature gametocytes and oocysts of P. falciparum were explored to illustrate how the
question of transmission is addressed.
Fig 3. Parasite Reduction Ratio. The number of viable P. falciparum strain 3D7 (MR4) versus treatment time is compared between
ACT-451840 and a selection of standard antimalarials (data for the latter was previously reported in reference [24]). Data are the
mean ± SD of four independent replicates.
doi:10.1371/journal.pmed.1002138.g003
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Within the human host blood, P. falciparum gametocytes are classifiedmorphologically
into five stages, denoted I–V, whilst P. vivax gametocytes do not show the same morphology.
Although the various sexual stages do not cause clinical disease, stage V gametocytes are infec-
tive to mosquitoes. These gametocytes are not eliminated by the majority of current antimalar-
ial agents [25] and therefore remain circulating in the human bloodstream for up to 3 wk, well
after the disappearance of clinical symptoms of malaria [26]. Gamete formation is a functional
readout for the viability of the mature stage V gametocyte [27]. ACT-451840 potently pre-
vented male gamete formation from the gametocyte stage with an IC50 of 5.89 nM ± 1.80 nM
(SD), as shown in Fig 7.
Interestingly, ACT-451840 had no effect on the functional viability of female gametocytes
up to a concentration of 20 μM. Nevertheless, successful transmission requires viable gameto-
cytes of both sexes to be present, as seen similarly with two male-specificmolecules,
MMV007116 and MMV085203, that demonstrate transmission blocking in a standard mem-
brane feeding assay [27], supporting the potential of ACT-451840 to blockmalarial
transmission.
In line with this, ACT-451840 did indeed block transmission when tested in the standard
membrane feeding assay. In this assay, parasite cultures containing P. falciparum stage V
gametocytes were exposed to compound for 24 h prior to mosquito feeding. Seven days postin-
fection, control feeds showed an average parasite density of 26.2 oocysts per mosquito, which is
well within the range of oocyst densities observed in laboratory infections [28]. ACT-451840
dose-dependently blocked oocyst development in the mosquito, with an IC50 of 30 nM (95%
confidence interval: 23–39 nM) (Fig 8A). At this parasite exposure, the prevalence of infection
Fig 4. Time-, stage-, and concentration-dependent effects of ACT-451840 on synchronous cultures of P. falciparum NF54 in vitro.
Parasites were exposed to ACT-451840 for 6 or 24 h at the indicated concentration. Results are expressed as the percentage of growth of the
respective development stage relative to an untreated control. Each bar represents the mean + SD of three independent experiments.
doi:10.1371/journal.pmed.1002138.g004
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(number of infectedmosquitoes) was inhibited, with an IC50 of 104 nM (95% confidence inter-
val: 98–110 nM) (Fig 8B).
As the parasite exposure in the field is much lower (1–3 oocysts/mosquito),ACT-451840
potencymight be underestimated and might have a greater effect on oocyst prevalence [29]. To
address the specific effect of the compound against the parasite forms that develop in the mos-
quito midgut, a different mode of standard membrane feeding assay was performed, in which
the compound was added to the parasite at the time of mosquito feeding.Here, ACT-451840
did not show any activity against P. falciparum oocysts at concentrations up to 1 μM (S2 Fig).
These data strongly suggest that the transmission-blocking effect of ACT-451840 relies on its
gametocytocidal activity.
Characterization of ACT-451840 Safety Profile: Initiation of Clinical
Studies
In order to initiate investigation in humans, the preclinical safety profile of ACT-451840 was
analyzed in dedicated toxicities studies performed in compliance with Good Laboratory Prac-
tice regulations and following the International Council for Harmonization guidelines. In
safety pharmacology studies, no effects on central nervous and respiratory parameters were
observed in rats dosed up to 1,000 mg/kg, and no effect on cardiovascular parameters were
observed in dogs dosed up to 500 mg/kg. ACT-451840 was not genotoxic when assessed in
vitro in a reverse mutation test or in a chromosome aberration study and in vivo in a micronu-
cleus test. In the general oral toxicity studies performedwith ACT-451840 for up to 4 wk, rats
Fig 5. Therapeutic efficacy against P. falciparum in vivo. Parasitemia in peripheral blood of mice infected with P. falciparum
NF540230/N3 and treated with vehicle, chloroquine, or ACT-451840 once daily for 4 d starting on Day 3 after infection. Data shown are
mean parasitemia of three mice/group. Abbreviations: 50% effective dose (ED50), 90% effective dose (ED90).
doi:10.1371/journal.pmed.1002138.g005
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Fig 6. In vivo efficacy (upper panel) and exposure (lower panel) of ACT-451840 against P. berghei. Doses were administered once per day except
for 2 x 15 mg/kg and 2 x 30 mg/kg, for which mice were dosed twice per day, with the second daily dose 8 h after the first dose. Abbreviations:
pharmacokinetic (PK), time to reach the maximum observed plasma concentration (Tmax), maximum observed plasma concentration (Cmax), area under
the concentration versus time curve (AUC).
doi:10.1371/journal.pmed.1002138.g006
Fig 7. P. falciparum dual gamete formation assay. The effect of ACT-451840 on the functional viability of P.
falciparum male and female gametocytes was tested in vitro in dose response. Male gametocyte viability was
reported by microscopic detection of exflagellation centers and yielded an IC50 of 5.89 nM ± 1.80 nM (SD). ACT-
451840 showed no activity against female gametocytes, as reported by the surface expression of the female
gamete marker pfs-25. Data shown are the mean of four independent replicates. Error bars indicate SE.
doi:10.1371/journal.pmed.1002138.g007
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and dogs were dosed up to 2,000 mg/kg/day and 1,000 mg/kg/day, respectively. There was no
evidence of local gastrointestinal toxicity. The no-observed-adverse-effectlevels were estab-
lished at 100 mg/kg/day in both species based on reduced body weight gain and clinical chem-
istry and histology findings, respectively. Based on these results, safety margins were calculated
to cover the whole dose range to be tested in the single ascending dose Phase I study.
Translation of PD and PK Data from Animal Models into Man
Towards the goal of initiation of a POC study and based on the results from the P. falciparum
and P. bergheimalaria mouse models, the human effective dose was predicted. The approach
to model the PK/PD relationship is illustrated in Fig 9.
As a first step, PK parameters of ACT-451840 were determined in healthy mice after a single
oral dose of 10, 100, and 300 mg/kg body weight. The PK parameters were calculated and are
shown in Table 2.
To assess the PK parameters in infectedmice, blood samples were taken at 1, 4, and 24 h
after the first dose of a triple-dose regimen in the P. berghei efficacy studies. The employed
doses were 15 or 30 mg/kg bis in die (b.i.d.), and 30, 50, 100, 300 mg/kg quaque die (q.d.)
(n = 3/timepoint and dose). No significant difference in blood concentration was found
between the time points studied in infectedmice compared to those in healthy mice (S3 Fig).
In order to analyze the PK/PD relationship, drug exposure was predicted for all tested doses
in P. bergheimouse model using a single compartment model with saturable absorption based
on the concentration–time profile observed after 10, 100, and 300 mg/kg single-dose regimen
in healthy mice. PK model parameter estimates are shown in Table 3.
The PK model was used to predict the blood PK parameters for all dosing regimens used in
the P. bergheimouse model, as shown in Fig 6 and S2 Text.
The next step was to determine which of the PK parameters (Cmax, AUC, or time above a
threshold concentration) was driving the curative efficacy of ACT-451840 in the P. berghei
mouse model. To establish this PK/PD relationship, the predicted and measured PK properties
were used to model curative efficacy in relation to AUC, Cmax, and time over a threshold con-
centration of 1,000 ng/mL. This threshold was defined as the minimum concentration needed
to significantly increase the survival of mice treated with ACT-451840 after both single- and
Fig 8. ACT-451840 blocking transmission. Standard membrane feeding assays were performed with a 24 h pre-incubation of gametocytes with
compound (indirect mode). (A) shows average oocyst intensity per mosquito and (B) shows average oocyst prevalence (percentage of
mosquitoes with at least one oocyst). Error bars indicate SE from the measurements of the two groups of the 20 mosquitoes per sample.
doi:10.1371/journal.pmed.1002138.g008
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triple-dose regimens over that of control animals. The value of 1,000 ng/mL was estimated
from the data in S2 Text, in which the triple-dose regimen of 10 mg/kg with a Cmax of 617 ng/
mL showed no increase in survival compared to control animals, whereas the triple-dose regi-
men of 30 mg/kg with Cmax of 1,670 ng/mL showed an increase in survival up to 13 d.
The PK/PD relationships for the P. berghei in vivo efficacy experiments are given in Fig 10
and Fig 11 and the resulting PK/PD parameters are shown in Table 4.
The best fit for predicted versus observedPK/PD relationship was found for AUC and time
above a threshold concentration versus survival, and time above a threshold concentration ver-
sus antimalarial activity, as illustrated by the correlation coefficients0.96 (Table 5).
Survival and AUC were selected as parameters for the predictions in human. Survival is a
robust readout and the relevant endpoint for clinical efficacy. AUC, rather than time above
threshold, was used because the threshold value was based on PD endpoint in infectedmice
with P. berghei and may be different in humans infected with P. falciparum.
Having established AUC as the driver for survival in the P. bergheimouse model, this
insight was used to predict an efficacious exposure against P. falciparum in humans with the
results of the P. falciparum mouse model. In the P. falciparum mouse model after a quadruple-
dose regimen, the ED90 of 3.7 mg/kg corresponded to a total AUC in blood of 227 ngh/mL
(linearly extrapolated from the exposuremeasured at a single dose of 4.7 mg/kg). The total
Fig 9. PK/PD strategy. Workflow of PK and PD modeling approach towards human efficacious dose prediction. Abbreviations: maximum
observed plasma concentration (Cmax) and, area under the concentration versus time curve (AUC).
doi:10.1371/journal.pmed.1002138.g009
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AUC giving an ED90 in the P. bergheimodel (16,300 ngh/mL after a triple-dose regimen of 13
mg/kg) was 23-fold lower than the total AUC giving cure (377,000 ngh/mL after a triple-dose
regimen of 300 mg/kg). Using this factor, the efficacious human total AUC was estimated to be
227 x 23 = 5,250 ngh/mL, expressed in mouse blood. Correcting for the measured blood/
plasma ratio of 0.6 (S3 Text), this corresponds to a predicted total efficacious human plasma
AUC of 8,750 ngh/mL. This exposure is about six times the exposure (1,408 ngh/mL)
observed after a single 500 mg dose in fed human subjects [30].
Discussion
This report presents results from vitro and in vivo experiments to preclinically characterize a
novel antimalarial compound (ACT-451840). The data shown here indicate that ACT-451840
shares many of the favorable MMVTCP1 properties of artemisinin and its derivatives, such as
its potency against P. falciparum and P. vivax, fast onset of action, activity against all asexual
erythrocytic stages, and PRR of>4 log per cycle of asexual blood stage forms. In addition,
although the potency observed in the standard membrane feeding assay was 10-fold lower than
the potency of the compound against asexual blood stage parasites, ACT-451840's gametocyto-
cidal activity blocks transmission, fulfilling the properties requested for a TCP3b [8].
In the global portfolio of malaria medicines, other recently discovered novel compounds are
the synthetic peroxide OZ439 [18], the spiroindolone KAE609 [31], the imidazolopiperazines
KAF156 [32], the dihydroorotate dehydrogenase inhibitor DSM265 [33], and the translation
elongation factor 2 inhibitor DDD107498 [23]. ACT-451840 shares the fast-acting properties
[34] with OZ439 and KAE609, which are both foreseen to be part of a single-exposure radical
cure product, as the compounds fit the TCP1, 3b and TCP1, 2 and 3b, respectively [7,35].
Although KAF156 and DDD107498 share the transmission-blocking characteristics with
ACT-451840, both are seen to be agents with potential for chemoprophylaxis due to their in
vitro activity against liver schizonts [23,36]. Finally, DSM265 exhibits properties of a TCP 2,
positioning this compound with its long duration as potential partner of a single-exposure
combination, in addition to its prophylaxis potential (TCP4) [33].
In contrast to the artemisinins, the here described compound class acts through a distinct
mode of action by interacting with the P. falciparum multidrug resistance protein-1 [4,5].
Table 2. Pharmacokinetics parameters of ACT-451840 in healthy mice (n = 4).
Pharmacokinetic parameters measured
Dose (mg/kg) Tmax (h) Cmax (ng/mL) AUC (ng/mL*h)
10 2.5 415 ± 20% 1,780 ± 18%
100 6 3,910 ± 20% 32,900 ± 36%
300 7 7,010 ± 32% 60,900 ± 33%
Abbreviations: time to reach the maximum observed plasma concentration (Tmax), maximum observed plasma concentration (Cmax), area under the
concentration versus time curve (AUC).
doi:10.1371/journal.pmed.1002138.t002
Table 3. Parameterization of the pharmacokinetic model.
Parameter estimation of the mouse pharmacokinetic model
Volume of distribution/bioavailability (L/kg) 4.3
Clearance/bioavailability (L/h) 2.4
Max Absorption (ug/h/kg) 21
Concentration at half the maximal absorption (ug/mL) 64
doi:10.1371/journal.pmed.1002138.t003
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Combined with the finding that ACT-451840 was well tolerated in a recent single ascending
dose study and exhibited a much longer terminal half-life than artemisinin, comparable to
OZ439 (34 h, 2 h, and 25–30 h, respectively) [30,37,38], this novel compound has the potential
to be used as a substitute for the artemisinin derivatives in combination treatments. Addition-
ally, the in vitro activity against artemisinin-resistant strains positions ACT-451840 as a strong
candidate in the race for malaria eradication.
PD properties of ACT-451840 were interpreted in two mouse models of malaria with
respect to the PK properties, with the objective to establish the portable PK/PD parameters to
estimate efficacious exposure following similar methodology validated with KAE609 [35]. In
this PK/PD approach, the robust endpoint of animal survival and cure were chosen for clinical
relevance. Using survival as endpoint, both AUC and time above a threshold concentration
Fig 10. Survival days of P. berghei infected mice plotted against AUC, Cmax, and time above threshold over the entire treatment period (1 or 3 d).
Dots are the observed days of survival; the line is the modeled relationship using a maximal effect (Emax) model.
doi:10.1371/journal.pmed.1002138.g010
Fig 11. Antimalarial activity in P. berghei infected mice plotted against AUC, Cmax, and time above threshold over the entire treatment period (1
or 3 d). Dots are the observed antimalarial activity; the line is the modeled relationship using a maximal effect (Emax) model.
doi:10.1371/journal.pmed.1002138.g011
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were drivers for efficacy. The AUC resulting in cure in the mousemodels was further translated
to a predicted efficacious exposure in man, which was actually about six times the exposure
observed after a single dose of 500 mg in fed state in healthy subjects. Two elements might give
prospect to this conservative prediction. Firstly, the threshold concentration specified in the
current PK/PD analysis (1,000 ng/mL in the P. bergheimodel) was defined as two times the
99% inhibitory concentration in a recent publication [35]. The alternative approach used to
assess efficacious concentrations in vivo calculated the minimum inhibitory concentration and
estimated a minimum parasiticidal concentration frommodeling of the exposure–efficacyin
the P. falciparum murine model. Because exposure was measured at a single dose of ACT-
451840, this method cannot be applied in this case. However, given P. berghei and P. falcipa-
rum differences, it is likely that both concentrations would be much lower for ACT-451840
than the threshold concentration in the P. bergheimodel. Considering the 99% inhibitory con-
centration of ACT-451840, the value of the threshold would be 1.8 ng/mL (2.4 nM) and would
be covered for 72 h, corresponding to one and a half asexual blood reproductive cycles, after a
single dose of 500 mg in fed state in healthy subjects. Secondly, the results of the phase I study
indicated the presence of circulating active metabolites with, on average, a 4-fold increase in
antimalarial activity [30]. Providing these active metabolites were not present in the malaria
murine model (not investigated) and, therefore, not taken into account for the human effica-
cious dose prediction, the overall antimalarial activity in humans dosed with ACT-451840
could be even higher than expected.
The aim of efficacious dose prediction is to provide guidance for the selection of optimal
doses to be investigated in POC clinical trials as monotherapy. Although artemisininmono-
therapy offers rapid recovery and fast parasite clearance [39], the use of combination therapy is
recommended to reduce the risk of recrudescence associated with monotherapy, which is high
for treatment regimens less than 7 d in length [40], and to decrease the potential development
of drug resistance [41]. This approach allowed short-course combination therapies to be
deployed with excellent efficacy, tolerability, and adherence, as illustrated with the lumefan-
trine/artemether combination therapy Coartem [42,43]. In addition, as fat intake enhances
Table 4. Pharmacodynamic parameters of ACT-451840 versus pharmacokinetic parameters.
Survival Antimalarial activity
EX50 E0 Emax EX50 Emax
AUC 170,000 (ng*h/mL) ± 16% 5.1 (day) ± 17% 35 (day) ± 35% 8,100 (ng*h/mL) ± 35% 110 (%) ± 8.3%
Cmax 15,000 (ng/mL) ± 170% 4 (day) ± 54% 62 (day) ± 120% 930 (ng/mL) ± 36% 130 (%) ± 11%
Time above threshold 150 (h) ± 52% 5.9 (day) ± 12% 70 (day) ± 71% 0.14 (h) ± 3,000% 100 (%) ± 38%
Data includes coefficient of variation. E0 and Emax are the minimal effect and maximal effect, respectively, with the effect being survival or antimalarial
activity. EX50 is the magnitude of X needed to achieve 50% of the maximal effect, with X being AUC, Cmax, or time above threshold.
doi:10.1371/journal.pmed.1002138.t004
Table 5. Correlation of the observed survival or antimalarial activity versus modeled maximal effect
relationship.
Correlation for survival (R2) Correlation for antimalarial activity (R2)
AUC 0.96 0.88
Cmax 0.85 0.91
Time above threshold 0.96 0.97
R2 = correlation between observed and predicted activity. Abbreviations: area under the concentration
versus time curve (AUC), maximum observed plasma concentration (Cmax).
doi:10.1371/journal.pmed.1002138.t005
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absorption, particularly for lumefantrine [44] and ACT-451840 [30], the development of a
lipid-based formulation in humans might be the next major improvement towards limiting the
variability and increasing exposure. Of note, work performed at Actelion Pharmaceuticals (S4
Text) has shown that the food effect observedwith ACT-451840 [30] could be mimicked by
the use of lipid-based formulations in fasted conditions in dog PK studies. Therefore, dose pre-
dictionmight be refined during the development of the future medicine with new formulation
and combination partners.
ACT-451840 has been tested as a monotherapy in an experimental human malaria infection
model, a clinical trial developed by MMV in partnership with QIMR Berghofer of Medical
Research Institute (Brisbane, Australia) [45]. The dosing regimen for this POC study (500 mg
in fed condition) was constrained by the conditions tested in the phase I study. The results of
this study confirmed the fast action of ACT-451840 observed in in vitro and in vivo models
and its gametocytocidal effect. This validates that ACT-451840 might be a good candidate for
TCP1 and TCP3b in humans [34]. The future steps will consist of the development of a lipid-
based formulation, the selection of a combination partner, and the determination of the activity
of ACT-451840 in patients.
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